ABOUT THIS EVENT

Tyme Technologies, Inc. (Nasdaq: TYME), is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, TYME’s CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death. In clinical trials, TYME’s lead pipeline candidate, SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, prostate, sarcoma, breast, lung, and lymphoma cancers with minimal serious grade 3 or higher adverse events. TYME visited the Nasdaq MarketSite in Times Square.

In honor of the occasion, Michele Korfin, TYME’s Chief Operating Officer, rang the Opening Bell.